Please assess the completion status of the following clinical trial:

Trial Title: AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Trauma patients between the ages of 18 and 65 who require 6 or more units of blood product during their initial 12 hours of resuscitation will be considered for enrollment.~Exclusion Criteria:~* Patients with a traumatic brain injury requiring neurosurgical operative intervention or who have neurologic trauma deemed non-survivable will also be excluded.~* Patients with an active coronary syndrome, history of myocardial infarction or coronary artery disease will be excluded.~* Patients with known renal dysfunction requiring dialysis will be excluded.~* Patients who are pregnant will be excluded.~* Patients less than 18 years old will be excluded.~* Patients who have opted out by bracelet identification or by listing themselves on the Non-Participant roster.~* Patients under the jurisdiction of the department of corrections and considered prisoners prior to the initiation of the research intervention will be excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Vasopressin (Type: ACTIVE_COMPARATOR): Vasopressin will be given as an initial bolus (4 Units) followed by an infusion titrated between 0 units/min to 0.04 units per min to maintain a mean arterial blood pressure greater than or equal to 65 mmHg
- Normal Saline (Type: PLACEBO_COMPARATOR): An initial bolus of normal saline will be given (10 cc) and an infusion of 0.1 ml per minute will be started and titrated down in as the mean arterial blood pressure reaches 65 mmHg or more.

Based on this trial design, predict the completion outcome and termination type (if applicable).